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Treating Atrial Fibrillation From Afar
Integrating Anatomic, Physiologic, Neurologic, and
Cardiovascular Principles Into Novel Therapies*Suraj Kapa, MD,y David J. Callans, MDzOne doesn’t discover new lands without consenting
to lose sight, for a very long time, of the shore.
—André Gide, Les faux-monnayeurs (1)I t is certainly difﬁcult to be a patient with atrialﬁbrillation (AF) or an electrophysiologist caringfor this patient. We live with the frustration
related to the seemingly capricious nature of ablation
success for AF, trapped in the hope that constructing
a slightly altered lesion set, using a newer catheter,
or processing signals differently will allow for a major
scientiﬁc breakthrough. In fact, the last 20 years of
research in AF have been characterized by a prepon-
derance of work on potentials and pulmonary veins.
More recently, however, we have come to again
appreciate the role of the autonomic nervous system
in cardiac arrhythmias—a role that has been well
recognized since the 1970s, starting with pioneering
work by Kapa et al. (2) and Coumel et al. (3). Though
initially considered a sympathetically mediated phe-
nomenon, further study led to the understanding
that parasympathetic effects on atrial dispersion as
well as sympathetic effects may be involved in AF
pathogenesis (4–6). In fact, the higher incidence of
AF during sleep has been felt to be due to a profound
parasympathetic dominance and, in turn, perhaps an*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.increased sympathetic drive converting to a vagal
predominance and AF onset (7,8).
Decades of large animal work by the University of
Oklahoma group has demonstrated a relationship
between the autonomic nervous system and phe-
nomena related to AF initiation and maintenance
(9–11). This relationship is borne out by simple anat-
omy: the highest density of nerve endings in the
human atria occur at the pulmonary vein/atrial
interface; the usual response of ablation at the pul-
monary veins is bradycardia rather than tachycardia;
and ganglionated plexi that relay vagal and sympa-
thetic efferents to myocardial cells are principally
distributed around the heart’s posterior surface
including in proximity to the pulmonary veins. This
has led to the assumption that ablation of such
ganglia and nerve endings may facilitate AF treat-
ment, though this has not been demonstrated
consistently in patient studies, potentially due to
the difﬁculty of identifying ganglia, the limitations
of existing ablation technology, and the potential
for reinnervation or nerve regrowth at the site of
successful ablation (12–14).
Alternative therapies were then proposed to not
just destroy autonomic inputs but to modulate their
activity through stimulation or ablation of extra-
cardiac structures. For example, low-level vagus
nerve stimulation (LLVNS) makes AF more difﬁcult to
induce by lengthening AF cycle length and prevent-
ing electrical (shortening of the atrial refractory
period and dispersion of refractoriness) and auto-
nomic remodeling (through burst ﬁring of cardiac
ganglionated plexi) caused by rapid atrial pacing
(15,16). These observations form the basis of the
“autonomic hypothesis”: hyperactivity of the cardiac
autonomic nervous system causes/maintains AF; in
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877turn, modulating the autonomic nervous system may
effectively treat AF. Supportive evidence comes from
animal studies as well as from human studies of spi-
nal cord stimulation, renal denervation, and vagal
stimulation (2,17,18).SEE PAGE 867The study by Stavrakis et al. (19) in this issue of
the Journal furthers this understanding via a novel,
elegant approach that allows for a noninvasive, non-
ablative, nonpharmacological therapy for AF. Study-
ing low-level transcutaneous electrical stimulation of
the auricular branch of the vagus nerve at the level of
the tragus, they demonstrated that AF inducible by
rapid atrial pacing could be suppressed. Furthermore,
such stimulation decreased levels of inﬂammatory
cytokines in patients with paroxysmal AF, whereas
having minimal effects on sinus rate, atrioventricular
nodal properties, or blood pressure. These patients
were studied under general anesthesia, so one must
wonder whether the “type” of AF reﬂected by
inducibility under general anesthesia necessarily re-
ﬂects what is seen clinically; inducibility or lack
thereof at the end of traditional ablation does not
correlate with risk of clinical recurrence (20). Whether
LLVNS is effective for patients with discrete subtypes
of AF remains to be determined.
Much work remains, as Stavrakis et al. (19)
mentioned. First, analysis of ambulatory patients is
necessary. This new study of LLVNS was done using
general anesthesia, meaning the comfort factor for
patients must be considered. Furthermore, it will be
critical to determine the level of stimulation required
to achieve the desired suppressive effect. In other
mammalian hearts, there is a parabolic effect on the
cardiac response, with low-level stimulation affecting
features of cardiac contractility differently than
higher outputs would (21). Whether this applies to
the heart’s electrical properties is less clear. In turn,
the relationship of injury to, or stimulation of, theauricular portion of the vagus nerve on cardiac
contractility and electrical function has been
described since the 1970s, where features such as
hypotension, increased ventricular ectopy, and even
right bundle branch block were associated with
manipulation and sectioning of the upper vagal
rootlets in patients (22). Thus, we must consider the
subtleties of this novel therapy because a simple
paradigm of stimulation on/off or high energy/low
energy may not offer a comprehensive enough un-
derstanding of its correct application. Therefore,
clinical studies of LLVNS must continue to be paired
with physiological studies to avoid getting caught in
the trap of advancing a therapy without ﬁrst ensuring
the structural integrity of its foundation.
We hope that Stavrakis et al. (19) are correct and
these lines of investigation will eventually lead to a
successful nonpharmacological, nonablative therapy
for AF. More importantly, this study aims at under-
standing the fundamental nature of AF and its patho-
physiology. Many have argued that electrophysiology,
once a mostly intellectual pursuit ﬁrmly grounded
in our understanding of physiology, has lost its way.
By rediscovering our past to help innovate our future,
we may be able to again harness the elegance of
the neural-cardiac interface to better manage our
patients—more safely, effectively, and thoughtfully.
Ultimately, the effectiveness of interventions on the
basis of this knowledge remains to be determined.
What is clear, however, is that there may be value to
electrophysiologists sometimes losing “sight of the
shore” of ablation therapy to discover new and
potentially more effective options for patient care.
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